NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Ziv-Aflibercept

Last Revision: June 15, 2020.

Estimated reading time: 1 minute

CASRN: 1609655-49-3

Drug Levels and Effects

Summary of Use during Lactation

This record refers to the use of ziv-aflibercept for treating cancer. No information is available on the use of ziv-aflibercept during breastfeeding. Because ziv-aflibercept is a large protein molecule with a molecular weight of 115,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. However, ziv-aflibercept is usually used in combination with other potentially toxic chemotherapy agents and most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. Intravitreal aflibercept decreased vascular endothelial growth factor in breastmilk in one woman.[1] Since VEGF is present in human milk and is thought to help in maturation of the infant’s gastrointestinal tract, concern has been raised about the maternal use of VEGF inhibitors during breastfeeding. Note that the typical alternative to breastmilk is infant formula, which contains no VEGF.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Juncal VR, Paracha Q, Bamakrid M, et al. Ranibizumab and aflibercept levels in breast milk after intravitreal injection. Ophthalmology. 2020;127:278–80. [PubMed: 31526521]

Substance Identification

Substance Name

Ziv-Aflibercept

CAS Registry Number

1609655-49-3

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Angiogenesis Inhibitors

Recombinant Fusion Proteins

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Aflibercept[Drugs and Lactation Database (...]
    Review Aflibercept
    . Drugs and Lactation Database (LactMed). 2006
  • Review Brolucizumab[Drugs and Lactation Database (...]
    Review Brolucizumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Bevacizumab[Drugs and Lactation Database (...]
    Review Bevacizumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Ranibizumab[Drugs and Lactation Database (...]
    Review Ranibizumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact.[Asia Pac J Ophthalmol (Phila)....]
    Review Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact.
    Singh SR, Dogra A, Stewart M, Das T, Chhablani J. Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec; 6(6):561-568. Epub 2017 Oct 3.
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...